Monitor for Form 144 filings or changes in trading plans; current sales are small relative to company size and likely routine, but continued selling could signal reduced confidence.
NVCR drugs
NVCR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 27 $13.67entry
- T+1 · 9mo ago −1.10%α −1.15% · $13.52
- T+5 · 9mo ago −4.61%α −2.63% · $13.04
- T+20 · 8mo ago −19.75%α −12.20% · $10.97
- T+60 · 6mo ago +33.58%α +24.19% · $18.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple NovoCure executives, including CEO Leonard Frank X and CMO Weinberg Uri, conducted open-market share sales totaling $441,770 over the past seven days, concurrent with routine stock grants and tax-related share surrenders. The selling activity is modest in dollar value and appears consistent with pre-arranged trading plans or diversification, rather than a coordinated negative signal.
Key Financial Metrics
Key Facts
- CEO Leonard Frank X sold $230,585 worth of shares in two transactions (7,232 shares at $13.49 and 9,734 shares at $13.66).
- CMO Weinberg Uri sold $146,863 in shares (3,272 at $13.33 and 7,461 at $13.84).
- CHRO Puri Michal Nath sold $34,325 in shares and was granted 40,100 shares (non-cash).
- COO Paravasthu Mukund sold $26,752 in shares.
- Former CEO Cordova Ashley had two tax withholding events totaling $191,633 (13,951 shares).
- Executive Chairman Doyle received a non-cash grant of 200,000 shares.
- Total open-market sales by insiders: $441,770 over 7 days.
- Total value of non-cash transactions (grants, tax withholding): $423,272.
Financial Impact
$441,770 in open-market sales over 7 days (~0.03% of $1.5B market cap)
Risk Factors
- Perception of insider selling may weigh on sentiment if misinterpreted.
- Concentration of sales among top executives (CEO, CMO) could raise questions if volume increases.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (16 trades, 7d window) | cluster-NVCR-1772746315399 |
Track record
20 reports on NVCR
5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +19.75% at T+20 after the Feb 27, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
- Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
- Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
- Jun 30, 202619w ago 8-K Bullish 7/10 Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers